Literature DB >> 25941600

Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients.

Yoshihiro Ohue1, Hisashi Wada2, Mikio Oka1, Eiichi Nakayama3.   

Abstract

Immune responses to tumor antigens have been reported in cancer patients. However, the relevance of such spontaneous immune responses to the clinical course has not been studied extensively. We showed that the overall survival of patients with antibodies against NY-ESO-1 or XAGE1 (GAGED2a) antigen was prolonged in gastric or lung cancer patients, respectively.

Entities:  

Keywords:  NY-ESO-1; XAGE1 (GAGED2a); cancer/testis (CT) antigen; overall survival; spontaneous antibody response

Year:  2014        PMID： 25941600      PMCID： PMC4292217          DOI： 10.4161/21624011.2014.970032

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.

Authors:  Ali O Gure; Ramon Chua; Barbara Williamson; Mithat Gonen; Cathy A Ferrera; Sacha Gnjatic; Gerd Ritter; Andrew J G Simpson; Yao-T Chen; Lloyd J Old; Nasser K Altorki
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

2.  Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody.

Authors:  Yoshihiro Ohue; Koji Kurose; Yu Mizote; Hirofumi Matsumoto; Yumi Nishio; Midori Isobe; Minoru Fukuda; Akiko Uenaka; Mikio Oka; Eiichi Nakayama
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

3.  Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.

Authors:  Martina Müller; Martina Meyer; Tobias Schilling; Ernst Ulsperger; Thomas Lehnert; Hanswalter Zentgraf; Wolfgang Stremmel; Martin Volkmann; Peter R Galle
Journal:  Int J Oncol       Date:  2006-10       Impact factor: 5.650

Review 4.  NY-ESO-1: review of an immunogenic tumor antigen.

Authors:  Sacha Gnjatic; Hiroyoshi Nishikawa; Achim A Jungbluth; Ali O Güre; Gerd Ritter; Elke Jäger; Alexander Knuth; Yao-Tseng Chen; Lloyd J Old
Journal:  Adv Cancer Res       Date:  2006       Impact factor: 6.242

5.  Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.

Authors:  Benjamin Weide; Alexander Martens; Henning Zelba; Christina Stutz; Evelyna Derhovanessian; Anna Maria Di Giacomo; Michele Maio; Antje Sucker; Bastian Schilling; Dirk Schadendorf; Petra Büttner; Claus Garbe; Graham Pawelec
Journal:  Clin Cancer Res       Date:  2013-12-09       Impact factor: 12.531

6.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27

7.  Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.

Authors:  J P Pandey; A M Namboodiri; Y Ohue; M Oka; E Nakayama
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

8.  Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.

Authors:  Takemasa Tsuji; Junko Matsuzaki; Erika Ritter; Anthony Miliotto; Gerd Ritter; Kunle Odunsi; Lloyd J Old; Sacha Gnjatic
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

9.  NY-ESO-1 antibody as a novel tumour marker of gastric cancer.

Authors:  S Fujiwara; H Wada; J Kawada; R Kawabata; T Takahashi; J Fujita; T Hirao; K Shibata; Y Makari; S Iijima; H Nishikawa; A A Jungbluth; Y Nakamura; Y Kurokawa; M Yamasaki; H Miyata; K Nakajima; S Takiguchi; E Nakayama; M Mori; Y Doki
Journal:  Br J Cancer       Date:  2013-02-12       Impact factor: 7.640

10.  Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer.

Authors:  Sayeema Daudi; Kevin H Eng; Paulette Mhawech-Fauceglia; Carl Morrison; Anthony Miliotto; Amy Beck; Junko Matsuzaki; Takemasa Tsuji; Adrienne Groman; Sacha Gnjatic; Guillo Spagnoli; Shashikant Lele; Kunle Odunsi
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240
  10 in total
  8 in total

1.  B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies.

Authors:  Hans A Schlößer; Martin Thelen; Axel Lechner; Kerstin Wennhold; Maria A Garcia-Marquez; Sacha I Rothschild; Elena Staib; Thomas Zander; Dirk Beutner; Birgit Gathof; Ramona Gilles; Engin Cukuroglu; Jonathan Göke; Alexander Shimabukuro-Vornhagen; Uta Drebber; Alexander Quaas; Christiane J Bruns; Arnulf H Hölscher; Michael S Von Bergwelt-Baildon
Journal:  Oncoimmunology       Date:  2018-11-02       Impact factor: 8.110

2.  Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading.

Authors:  Ai Miyamoto; Tomoko Honjo; Mirei Masui; Rie Kinoshita; Hiromi Kumon; Kazuhiro Kakimi; Junichiro Futami
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

3.  Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.

Authors:  Jan Aleksander Kraśko; Karolina Žilionytė; Adas Darinskas; Neringa Dobrovolskienė; Agata Mlynska; Svetlana Riabceva; Iosif Zalutsky; Marina Derevyanko; Vladimir Kulchitsky; Olga Karaman; Natalia Fedosova; Tatiana Vasyliyvna Symchych; Gennady Didenko; Vasyl Chekhun; Marius Strioga; Vita Pašukonienė
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

4.  Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma.

Authors:  Zhen Zhang; Fan-Fan Li; Ming-Dian Lu; Shang-Xin Zhang; Yong-Xiang Li
Journal:  Oncotarget       Date:  2017-11-15

5.  Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

Authors:  Jean-François Baurain; Caroline Robert; Laurent Mortier; Bart Neyns; Florent Grange; Céleste Lebbe; Fernando Ulloa-Montoya; Pedro Miguel De Sousa Alves; Marc Gillet; Jamila Louahed; Silvija Jarnjak; Frédéric F Lehmann
Journal:  ESMO Open       Date:  2018-07-25

6.  Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection.

Authors:  Ruochuan Zang; Yuan Li; Runsen Jin; Xinfeng Wang; Yuanyuan Lei; Yun Che; Zhiliang Lu; Shuangshuang Mao; Jianbing Huang; Chengming Liu; Sufei Zheng; Fang Zhou; Qian Wu; Shugeng Gao; Nan Sun; Jie He
Journal:  Oncoimmunology       Date:  2019-07-08       Impact factor: 8.110

Review 7.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

8.  Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis.

Authors:  Vandeclecio Lira da Silva; André Faustino Fonseca; Marbella Fonseca; Thayna Emilia da Silva; Ana Carolina Coelho; José Eduardo Kroll; Jorge Estefano Santana de Souza; Beatriz Stransky; Gustavo Antonio de Souza; Sandro José de Souza
Journal:  Oncotarget       Date:  2017-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.